TISIDB

Summary
Symbol	FARP2
Name	FERM, RhoGEF and pleckstrin domain protein 2
Aliases	KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location	2q37.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	-
Domain	PF08736 FERM adjacent (FA) PF09380 FERM C-terminal PH-like domain PF00373 FERM central domain PF09379 FERM N-terminal domain PF00169 PH domain PF00621 RhoGEF domain
Function	Functions as guanine nucleotide exchange factor that activates RAC1. May have relatively low activity. Plays a role in the response to class 3 semaphorins and remodeling of the actin cytoskeleton. Plays a role in TNFSF11-mediated osteoclast differentiation, especially in podosome rearrangement and reorganization of the actin cytoskeleton. Regulates the activation of ITGB3, integrin signaling and cell adhesion (By similarity).

> Gene Ontology [ TOP ]
Biological Process	GO:0002521 leukocyte differentiation GO:0002573 myeloid leukocyte differentiation GO:0007265 Ras protein signal transduction GO:0007266 Rho protein signal transduction GO:0016322 neuron remodeling GO:0016601 Rac protein signal transduction GO:0021700 developmental maturation GO:0030099 myeloid cell differentiation GO:0030316 osteoclast differentiation GO:0031532 actin cytoskeleton reorganization GO:0033622 integrin activation GO:0033623 regulation of integrin activation GO:0035023 regulation of Rho protein signal transduction GO:0042551 neuron maturation GO:0043254 regulation of protein complex assembly GO:0046578 regulation of Ras protein signal transduction GO:0048469 cell maturation GO:0051056 regulation of small GTPase mediated signal transduction GO:0071526 semaphorin-plexin signaling pathway GO:0071800 podosome assembly
Molecular Function	GO:0005085 guanyl-nucleotide exchange factor activity GO:0005088 Ras guanyl-nucleotide exchange factor activity GO:0005089 Rho guanyl-nucleotide exchange factor activity GO:0030676 Rac guanyl-nucleotide exchange factor activity
Cellular Component	GO:0019898 extrinsic component of membrane

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04015 Rap1 signaling pathway hsa04520 Adherens junction
Reactome	R-HSA-422475: Axon guidance R-HSA-1266738: Developmental Biology R-HSA-399955: SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion R-HSA-373755: Semaphorin interactions

Summary
Symbol	FARP2
Name	FERM, RhoGEF and pleckstrin domain protein 2
Aliases	KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location	2q37.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between FARP2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	FARP2
Name	FERM, RhoGEF and pleckstrin domain protein 2
Aliases	KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location	2q37.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of FARP2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	FARP2
Name	FERM, RhoGEF and pleckstrin domain protein 2
Aliases	KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location	2q37.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of FARP2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0.867	0.0321
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	1.154	0.531
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0.664	0.607
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.105	0.739
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.079	0.968
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.138	0.956
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.331	0.322
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.603	0.682
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.03	0.985
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.25	0.819
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	1.233	0.403
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.017	0.831

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of FARP2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	11.1	4.1	7	0.339
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	7.1	-7.1	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	11.1	3.4	7.7	0.176
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	0	4.5	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	6.2	0	6.2	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	FARP2
Name	FERM, RhoGEF and pleckstrin domain protein 2
Aliases	KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location	2q37.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FARP2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	FARP2
Name	FERM, RhoGEF and pleckstrin domain protein 2
Aliases	KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location	2q37.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FARP2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FARP2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	FARP2
Name	FERM, RhoGEF and pleckstrin domain protein 2
Aliases	KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location	2q37.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FARP2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	FARP2
Name	FERM, RhoGEF and pleckstrin domain protein 2
Aliases	KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location	2q37.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of FARP2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	FARP2
Name	FERM, RhoGEF and pleckstrin domain protein 2
Aliases	KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location	2q37.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between FARP2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	FARP2
Name	FERM, RhoGEF and pleckstrin domain protein 2
Aliases	KIAA0793; PLEKHC3; FRG; FERM domain including RhoGEF; FGD1-related Cdc42-GEF; PH domain-containing family C ......
Chromosomal Location	2q37.3
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting FARP2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse FARP2